 Sydney, AUSTRALIA, Jan. 07, 2021 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for stage 2 of Part C of its TACTI-002 Phase II study. 